You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: The biotechnology industry is intensely competitive and subject to rapid and significant technological change. We believe that our pipeline, development experience and scientific knowledge provide us with competitive advantages. However, we face potential worldwide competition from many different sources, including large multinational pharmaceutical companies, established biotechnology companies and smaller or earlier stage biotechnology companies. In addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. Given the high incidence of NASH and obesity, it is likely that the number of companies seeking to develop products and therapies for the treatment of liver metabolic diseases, including NASH and obesity, will increase. We are aware of both pharmaceutical and biotechnology companies with development programs in CML. Companies that have recently participated in or are participating in the development of CML treatments include, but are not limited to, Ascentage Pharma Group, BristolMyers Squibb Company, Enliven Therapeutics Inc., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Novartis Pharmaceuticals Corp., Pfizer Inc., Shenzhen TargetRx Inc., Sun Pharma Industries Ltd., Takeda Pharmaceutical Co., Ltd. and Theseus Pharmaceuticals, Inc. We are aware of both pharmaceutical and biotechnology companies with development programs in NASH. Large pharmaceutical companies that have recently participated in or are participating in the development of NASH treatments include, but are not limited to, AbbVie, Inc., Amgen Inc., AstraZeneca PLC/MedImmune LLC, Bayer Assistant:
- Assistant
Positive: The biotechnology sector is highly competitive and experiences rapid and notable shifts in technology. We are confident that our pipeline, development expertise, and scientific acumen afford us competitive edges. Nonetheless, we encounter potential global competition from numerous sources, comprising large international pharmaceutical corporations, established biotech firms, and smaller or early-stage biotech companies. Moreover, academic institutions, government agencies, and other private and public entities conducting research might pursue patent protection for potentially competing products or technologies. Given the high prevalence of NASH and obesity, it is probable that more companies will aim to create products and therapies for liver metabolic diseases, including NASH and obesity. We recognize pharmaceutical and biotech companies with CML development initiatives. Companies recently involved or currently involved in CML treatment development include, among others: Ascentage Pharma Group, Bristol-Myers Squibb Company, Enliven Therapeutics Inc., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Novartis Pharmaceuticals Corp., Pfizer Inc., Shenzhen TargetRx Inc., Sun Pharma Industries Ltd., Takeda Pharmaceutical Co., Ltd., and Theseus Pharmaceuticals, Inc. We are also aware of pharmaceutical and biotechnology companies engaged in NASH development programs. Recent or active large pharmaceutical companies in NASH treatment development include, but are not limited to: AbbVie, Inc., Amgen Inc., AstraZeneca PLC/MedImmune LLC, Bayer.
Negative: The biotechnology sector is not competitive and experiences little to no change in technology. We doubt that our pipeline, development skills, and scientific knowledge give us any competitive benefits. We don't expect any global competition from external sources like big multinational pharmaceutical firms or smaller biotech entities. Academic bodies, governmental institutions, and research organizations are unlikely to seek patents for competing products or technologies. With low NASH and obesity incidences, fewer companies are expected to develop treatments for liver metabolic diseases, including NASH and obesity. We are unaware of pharmaceutical and biotechnology firms working on CML development. No recent participation from companies in CML treatment development is known, and there are no significant developments in the NASH treatment field from large pharmaceutical companies.